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REVIEW ARTICLE OPEN
Viral vector platforms within the gene therapy landscape
Jote T. Bulcha1,2, Yi Wang3, Hong Ma1, Phillip W. L. Tai 1,2,4 and Guangping Gao1,2,5
Throughout its 40-year history, the field of gene therapy has been marked by many transitions. It has seen great strides in
combating human disease, has given hope to patients and families with limited treatment options, but has also been subject to
many setbacks. Treatment of patients with this class of investigational drugs has resulted in severe adverse effects and, even in rare
cases, death. At the heart of this dichotomous field are the viral-based vectors, the delivery vehicles that have allowed researchers
and clinicians to develop powerful drug platforms, and have radically changed the face of medicine. Within the past 5 years, the
gene therapy field has seen a wave of drugs based on viral vectors that have gained regulatory approval that come in a variety of
designs and purposes. These modalities range from vector-based cancer therapies, to treating monogenic diseases with life-altering
outcomes. At present, the three key vector strategies are based on adenoviruses, adeno-associated viruses, and lentiviruses. They
have led the way in preclinical and clinical successes in the past two decades. However, despite these successes, many challenges
still limit these approaches from attaining their full potential. To review the viral vector-based gene therapy landscape, we focus on
these three highly regarded vector platforms and describe mechanisms of action and their roles in treating human disease.
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INTRODUCTION
Gene therapy is the treatment of a genetic disease by the
introduction of specific cell function-altering genetic material into
a patient. The key step in gene therapy is efficient gene delivery to
the target tissue/cells, which is carried out by gene delivery
vehicles called vectors. There are two types of vectors: viral and
non-viral. Non-viral vectors will not be discussed in this review.
Contemporary viral vector-based gene therapy is achieved by
in vivo delivery of the therapeutic gene into the patient by vectors
based on retroviruses, adenoviruses (Ads) or adeno-associated
viruses (AAVs) (Fig. 1). Alternatively, a therapeutic transgene can
be delivered ex vivo, whereby cells of a patient are extracted and
cultured outside of the body. Cells are then genetically modified
by introduction of a therapeutic transgene and are then re-
introduced back into the patient. There are four basic gene
therapy approaches as follows: gene replacement, the delivery of
a functional gene to replace a non-working gene; gene silencing,
inactivation of a mutated gene that has become toxic to cells;
gene addition, over expression of a “foreign” or exogenous gene
to impact cellular function; and gene editing, a permanent
manipulation of a gene in a patient’s genome.
The first gene therapy trial, at least conceptually, was performed
by Dr. Stanfield Rogers, who treated two sisters who had
hyperargininemia.1 The treatment was based on his observations
that patients with Shope papilloma virus had decreased serum
arginine levels. Unfortunately, the trial failed to reverse the
disease, as the Shope papilloma genome did not encode for
arginase production. In a 1980 study that was not formally
published, Dr. Martin Cline attempted to insert recombinant
β-globin, a factor needed in the production of hemoglobin, into
bone marrow cells of two patients with β-thalassemia.2 The
transfected cells were then re-introduced back into the patients.
Although groundbreaking at the time, this first attempt at an
ex vivo gene therapy was ultimately a failure. Nonetheless, these
two efforts were among several others that endeavored to deliver
genetic material to patients, in the hopes of treating disease. It
was not until the early 90s that viral vector gene therapies found
clinical success. A trial led by French Anderson, Michael Blaese,
and Steven Rosenburg also employed an ex vivo strategy in
treating a patient named Ashanthi DeSilva, who had adenosine
deaminase deficiency severe combined immunodeficiency dis-
ease (ADA-SCID). Several infusions of T cells transformed by a
recombinant retrovirus carrying the ADA gene were administered,
resulting in what is regarded as the first successful gene therapy in
humans.3,4
The use of viruses for therapy has long been practiced and
actually belongs to a class of viral-based treatments known as
virotherapies. Perhaps, the main reason why earlier viral-based
therapies failed to achieve efficacy was due to a lack of full
understanding of the viral biology. Now with 40 years of
accumulated knowledge on viruses, promising viral vector-based
strategies to treat genetic diseases are numerous. Some human
diseases even have several effective treatment options to choose
from. Typically, a viral vector is defined by three components as
follows: (1) the protein capsid and/or envelope that encapsidates
the genetic payload, and defines the vector’s tissue or cell tropism
and antigen recognition; (2) the transgene of interest, which when
expressed in cells, serves to confer a desired effect; and (3) the
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“regulatory cassette,” the combined enhancer/promoter/auxiliary
elements that controls stable or transient somatic expression of
the transgene as an episome or as a chromosomal integrant.
Design aspects for these three components are different for each
viral vector platform, have unique considerations, and harbor their
own strengths and weaknesses. In this review, we will describe
three viral vector platforms that have gained wide use for
efficacious gene therapy and regulatory approval. These three
strategies are based on Ads, AAVs, and lentiviruses (retroviruses),
the viruses that a majority of gene therapy vectors are based upon
(Fig. 2). For each of these vector platforms, we will review their
general compositions and their mode of infection, highlight key
vector platforms and their biological properties, describe current
production strategies in use, feature their uses as commercialized
drugs and in clinical trials, and finally discuss challenges and
future outlooks.
Ad vectors: large cargo capacities for transient targeted gene
delivery
Structure and genome. Ad is a non-enveloped virus that is known
to mostly cause infections of the upper respiratory tract but can
also infect other organs such as the brain and bladder. It possesses
an icosahedral protein capsid that accommodates a 26- to 45-kb
linear, double-stranded DNA genome. The Ad genome is flanked
Fig. 1 Summary of viral gene therapy modalities. In vivo gene therapy entails the direct administration of vector carrying a therapeutic
transgene into the patient. Ex vivo gene therapy involves the extraction of a patient’s cells or from an allogenic source, genetic modification
by a vector carrying a therapeutic transgene, selection and expansion in culture, and infusion to re-introduce the engineered cells back into
the patient
Fig. 2 Summary of viral vectors used in clinical trials. a Pie chart showing the percentage of adenovirus, adeno-associated virus, or lentivirus
vectors in use. b A table of the current number of clinical trials employing the different viral vectors. Data source: Wiley database on Gene
Therapy Trials Worldwide. http://www.abedia.com/wiley/vectors.php
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by hairpin-like inverted terminal repeats (ITRs) that vary in length
(30–371 bp at its termini).5,6 The ITRs serve as self-priming
structures that promote primase-independent DNA replication. A
packaging signal located at the left arm of the genome is required
for viral genome packaging. The Ad genome encodes ~35
proteins that are expressed in the early and late phases of viral
gene transcription. The Ad genome comprises five so-called
“early-phase” genes, E1A, E1B, E2, E3, and E4.7 The early-phase
genes are transcribed before the initiation of viral DNA replication
(about 7 h post infection). The “immediate-early” E1A gene is
essential for transcription of other viral genes (e.g., E1B, E2, E3, and
E4), which are responsible for viral DNA synthesis and play roles in
modulating expression of host genes. E1B plays roles in counter-
acting the cell’s activation of apoptosis by binding and inactivat-
ing p53, permitting viral replication to progress.8 The “late-phase”
genes (L1–L5) are generally required for virus assembly, release,
and lysis of the host cell.9 These gene products are derived from
the five late transcriptional units that are produced by alternative
splicing and polyadenylation of the major late messenger RNAs
(Fig. 3a).10
The Ad viral capsid is 90–100 nm in diameter. It is composed of
the structural proteins, hexon (capsid protein II), penton base
(capsid protein III), fiber (capsid protein IV), capsid protein
precursors pIIIa, pVI, and pVIII, and capsid protein IX, and the
virion core proteins (V, VII, and X).11 Hexons are the most
abundant structural components residing on the surface of the
virus, comprising 240 trimers in the assembled capsid. There are
12 penton proteins located at the apex of the icosahedral vertices,
giving rise to the protruding fibers. The V, VII, and X proteins
mainly associate with the viral genome and play critical roles in
genome replication, condensation, and assembly processes.11 The
IIIa proteins are located at the inner surface of capsid, and drive
the assembly of the packaged genome via binding with L1 52/55K
and stabilization of the vertex regions via interaction with penton
base, hexon, and VI proteins.12,13 The VI proteins link the core to
the inner icosahedral shell, while also serving as lytic factors
during endosomal disruption.14 The VIII proteins bind to the
peripentonal hexons to stabilize the viral capsid.15 The terminal
protein (pTP) covalently links to the 5′-ends of the Ad genome and
enhances genome replication.16
Ad assembly is thought to proceed by the following sequential
pathway steps: (1) empty capsids (procapsids) are assembled with
capsomers (hexons, penton bases, and fibers) along with some
minor capsid proteins and unstructured proteins; (2) the viral
genome binds to packaging proteins (IVa2, L4 33K, L1 52/55K, and
L4 22K) via the packaging signal (ψ) within the left ITR; (3)
Fig. 3 Schematic of the wild-type adenovirus type 5 (Ad5) genome and the genetic modifications of common Ad5-based vectors. a
Diagram of the wild-type Ad5 genome structure. The 36 kb genome consists of four early transcription elements (E1, E2, E3, and E4), five late
expression genes (L1–L5), cis-packaging elements (ψ) and two inverted terminal repeat sequences (ITR). The E1A (red arrow) gene contains
four conserved domains (CR1-4), each of which interacts with special cellular proteins. The E1B gene encodes for two distinct tumor antigens,
the 19 kDa (19K) and 55 kDa (55K) proteins. The E2 gene encodes DNA-binding protein (DBP), terminal protein (pTP), IVa2, and DNA
polymerase (Pol). The E4 gene encodes 1–7 open reading frames. The major late messenger RNAs (L1–L5) mainly encode for virion structural
proteins and are derived from a pre-mRNA, which is driven by a major late promoter (MLP) via alternative splicing and polyadenylation. L1
encodes for IIIa and 52K. L2 encodes for the penton base gene (capsid protein III) and the core proteins V, pVII, and pX. L3 encodes for the
hexon (capsid protein II), capsid protein precursor (pVI), and protease (Pr) genes. L4 encodes for 100K, 33K, 22K, and pVIII. L5 encodes for the
fiber gene (capsid protein IV). b–e Diagrams of rAd vectors. b Replication-defective (RD) vector. The E1A and E1B regions are deleted and
replaced with an expression cassette containing an exogenous promoter and a transgene of interest (indicated by the solid red X and yellow
arrow). The E3 and E4 regions are usually deleted to accommodate larger insertions and eliminates leaky expression of other viral genes.
c E1B-55K replication-competent vector. The E1B-55K region is deleted (solid red X and dashed blue arrow), whereas in some vectors, the E3
region is deleted and replaced with an expression cassette (dashed red X and dashed blue arrow). d E1A-Δ24 (Δ24) replication-competent
vector. The CR2 region in E1A is deleted (solid red X and dashed red arrow) and the E1A promoter can be replaced with various tumor-specific
promoters to drive CR2-deleted E1A expression. In some vector designs, the E3 region is deleted and replaced with an expression cassette
(dashed red X and dashed blue arrow). e Helper-dependent Ad vectors (HDAds). Most or all of the Ad genomic elements are replaced with a
therapeutic expressing cassette (yellow arrow), save for the cis-packaging sequences (ψ) and ITRs. These vectors are propagated in the
presence of an Ad helper vector
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encapsidation of the viral genome into the procapsid through a
hypothetical portal located at a unique vertex that is accompanied
by the release of scaffolding and some of the packaging proteins;
and (4) cleavage of the precursor proteins (pIIIa, L1 52/55K, pVI,
pVII, pVIII, mu, and pTP) by the adenovirus protease (AVP),
resulting in the final mature viral particle. Two to 3 days after
entering the cell nucleus, new virions are assembled and cells lyse
to release virions.17
Infection pathway. To date, more than a hundred human Ad
genotypes have been identified, falling into seven subgroups
classified A to G (http://hadvwg.gmu.edu). Knowledge on the Ad
infection pathway is largely based on human Ad5 (HAd5).
Infection initiates with interaction between the cell surface-
localized coxsackievirus-Ad receptor (CAR) and the distal domain
of the virus capsid fiber.18,19 In addition, many other receptors for
entry of Ads have also been found, such as CD46, DSG2, and sialic
acid.20–22 Binding of the virus to the cell surface is then followed
by endocytosis, which is mediated by interaction between the
tripeptide Arg-Gly-Asp (RGD) motif in the penton base and the αV
integrins on the host cell surface.23 Following endocytosis, the
capsid is disassembled and the V and VI proteins facilitate
endosomal escape.14,24 The viral DNA subsequently enters the
nucleus through the nuclear envelope pore complex.25 In
addition, hexons from partially disrupted virions bind with dynein
motors to help the virus traffic to the nuclear pore via the
microtubular network.26 In the nucleus, the viral DNA predomi-
nantly remains epichromosomal and is not incorporated into the
host cell genome.27
Ad natural infections and pathological association. Most people
carry neutralizing antibodies (NAbs) against one or more of the
prevalent human Ad serotypes, as a result of exposure to Ads from
past infections.28,29 Ads typically result in asymptomatic responses
or lead to mild or severe disease in immunocompetent
individuals.30 Among the seven known species of human Ads,
species B and C are usually acquired in early childhood and cause
infections in the upper respiratory, gastrointestinal, and urinary
tracts. Some serotypes in species D cause epidemic keratocon-
junctivitis, whereas HAd4 from species E causes acute respiratory
disease.31 Due in part to the epidemiology of Ads in the human
population and Ad antigen-specific T cells, which result in the
lifelong immunity, vectors based on Ad tend to have compro-
mised potencies32,33 and trigger a stronger immunological
response compared to other viral vectors, such as those based
on AAV (discussed further below).
Ad as a vector in gene therapy. Ad vectors have the following
advantages: (1) high transduction efficiency, both in quiescent and
dividing cells; (2) epichromosomal persistence in the host cell; (3)
broad tropism for different tissue targets; and (4) and the
availability of scalable production systems.34 Contemporary Ad
vectors are derived from human serotypes HAd2 and HAd5. The
major objectives in Ad vector development are to overcome the
challenges associated with its widely pre-existing viral immunity
among the general population, life-threatening strong innate
immune responses to its capsid proteins, and robust adaptive
immune responses to de novo synthesized viral and transgene
products.35 Since the first generation of E1A-deleted Ad vectors
were established, various strategies have been developed to
improve their capacity, efficacy, gene transfer longevity, and
safety.
First generation. The first generation of Ad vectors were engineered
by replacing the E1A/E1B region with transgene cassettes that can be
up to 4.5 kb in length (Fig. 3b). Removal of the E1A gene results in the
inability of recombinant Ad (rAd) to replicate in the host cell.36
Therefore, complementary cell lines designed to express E1A and
E1B, such as HEK293, are needed for production.37 As the E3 region is
not required for viral propagation in cultured cells, the E1/E3 double-
deletion frees up more space for the transgene cassettes (6.5 kb in
length). The first generation of Ad vectors has two main
disadvantages as follows: (1) de novo expression of Ad proteins
can still activate the host immune response, causing clearance of
vector-transduced cells;38 and (2) possible spontaneous homologous
recombination between the vector and engineered E1 region from
HEK293 during genome amplification can generate replication-
competent adenovirus.
Second generation. Due to issues with first-generation Ad vectors,
researchers developed improved versions by further deleting the
other early gene regions (E2a, E2b, or E4), permitting additional
space for larger transgene cassettes (10.5 kb) (Fig. 3b). These new
vector designs include temperature-sensitive rAd vectors, gener-
ated by ablation of E2A-encoded DNA-binding protein,39,40 deletion
of the E2b-encoded DNA polymerase (Pol) protein,41,42 and deletion
of the E4 region.43 All of these Ad vectors were shown to have
significantly decreased late gene expression and elicit less of a
cytotoxic T-lymphocyte response when administered in vivo. As a
result, transgene expression was substantially prolonged in mice
compared to first-generation vectors.39–43 Again, the deleted genes
are complemented by engineered production cell lines. Unfortu-
nately, the deletion of E2 and/or E4 genes negatively affects viral
vector amplification, resulting in lower titers.44 This reduction is a
consequence of inefficient complementation of E2/4 with engi-
neered cell lines. Despite the changes, the native Ad late genes that
are still retained within the vector genome can trigger host
immunogenicity and cellular toxicity.45
Third generation. Third-generation Ad vectors, referred to as
“gutless” or “helper-dependent” Ad vectors, have all viral sequences
deleted, except for the ITRs and the packaging signal (Fig. 3e).
These vectors, also called “high-capacity” adenoviral vectors
(HCAds),46 can accommodate ~36 kb of space for cargo gene(s).
Production of HCAds in cell culture requires an additional
adenoviral helper virus (HV) that is similar in composition to first-
generation vectors, but with the distinction that they contain loxP
sites inserted to flank the packaging signal. The HCAd genome is
transfected into HEK293 producer cells that express Cre recombi-
nase, along with the HV infection. Replication and packaging are
permitted by the viral proteins provided by the helper genome. The
engineered Cre in producer cells ensures that only the HCAd
genome can be packaged, as the helper-virus genome-packaging
signal is excised by Cre-mediated recombination at the loxP sites.47
Compared with the previous generations of Ad vectors, HCAds have
reduced immunogenicity, prolonged transduction in the host cell,
and a significantly larger cargo capacity, which can accommodate
multiple transgene cassettes, or therapeutic genes that are driven
by their larger native promoters and enhancers to mimic
physiological levels of expression. However, the main challenge in
HCAd production is ensuring that the helper adenovirus is
eliminated from vector preparations, which may alter efficacy and
safety of HCAd vectors in vivo.
Conditionally replicating Ad vectors. The engineering of tumor-
specific gene promoters into the Ad genome can be used to control
the initiation of viral replication to create conditionally replicative
adenoviral vectors (CRAds). The first CRAds were based on the
partial deletion of the E1B sequence (E1B-55K) (Fig. 3c).48 As viral
genome replication can be completed without E1B-55K in most
tumor cells, as they lack p53, E1B-55K-deleted Ads only undergo
genome amplification and subsequent lysis in a patient’s tumor
cells, leaving non-tumor cells unaffected. In the next generation of
CRAds, the 24-amino acid CR2 domain of E1A protein was deleted
to generate AdD24 vectors (Fig. 3d).49 The CR2 domain is known to
bind retinoblastoma protein to release E2F, the S-phase-activating
transcription factor required for viral genome replication in normal
cells. As cancer cells express excessive amount of E2F, Ad
replication can proceed without E1A. The resulting dl922-947 and
AdD24 vectors both showed high replication potency and
Viral vector platforms within the gene therapy landscape
Bulcha et al.
4
Signal Transduction and Targeted Therapy            (2021) 6:53 
selectivity in tumor cells.50 These oncolytic Ad vectors are unique
from other natural oncolytic viruses such as reoviruses, seneca-
viruses, and the α-virus M1 virus.51,52 Improvements to tumor
specificity through these engineering efforts have inherent
advantages over natural viruses, as natural viruses carry wild-type
viral genomes that may result in unknown consequences.
Therapeutic Ad vectors and commercial availability. In the early
1990s, Ad vectors for in vivo therapy were first used to deliver and
express the α-1 antitrypsin (A1AT) gene in rat hepatocytes and
lung tissues.53,54 Following this demonstration, many Ad-based
gene delivery trials for treating human monogenic disease were
conducted, including the expression of cystic fibrosis transmem-
brane conductance regulator (CFTR) in lung tissues of patients
with cystic fibrosis, and vascular endothelial growth factor (VEGF)
in patients with peripheral vascular disease.55,56 Unfortunately, a
series of studies revealed that Ad is strongly immunogenic, which
not only restricted the delivery and expression of exogenous
genes but also caused undesired immune responses in treated
subjects.57 Soon after in 1999, the death of Jesse Gelsinger, who
was enrolled in a clinical trial for OTC (ornithine transcarbamylase)
gene therapy with an Ad vector,58 raised safety concerns for
human gene therapies and caused a significant decline in related
studies for the following decade. It was discovered that innate
response to the capsid protein triggered cytokine storm.58 These
unfortunate results and backup evidence in animal models
indicated that even with gutless rAd designs, the capsid may still
trigger a strong immune response towards the therapy,59,60 thus
limiting the use of Ad vectors in human gene therapy.
It is now well-accepted that Ad can trigger strong immune
responses in humans, reinforcing safety concerns for their applica-
tion.61 However, for therapies that are not impacted by an
immunological response, but may even rely on them to kill the cells
they transduce, Ad vectors have seen significant utility. For example
in 2003, Gendicine, an Ad vector harboring a Rous sarcoma virus
promoter-driven p53 gene, was approved in China as the world’s first
commercialized gene therapy drug for cancer.62 ONYX-105 (dl1520)
was the first CRAd to enter clinical trials,63,64 followed by a similar
replication-selective Ad vector called H101 (Oncorine), which also
gained commercial approval in China.65 Although numerous clinical
results have confirmed the safety of ONYX-105 and H101, the drugs
were ultimately not very effective. The major reason for the lowered
efficacies is that deletion of E1B-55K also causes attenuated viral
replication, even in tumor cells in vivo.
Ad vectors in clinical trials. Ad vectors have seen a rebirth in
human gene therapy research. They maintain many practical
advantages, including their broad tropism profiles, lack of host
genome integration, and large packaging capacities (~36 kb).
Currently, Ad-based gene therapy clinical trials account for 50%
of total worldwide trials (Fig. 2a). They have been mainly
applied towards novel vaccines and cancer therapies.
Ad-mediated genetic vaccines. Immunogenicity is a critical hurdle
for viral vector efficacy, but has been exploited in the develop-
ment of Ad-based vaccines.66 rAd vectors can deliver foreign
epitopes to enhance the host immune response to pathogens by
boosting the production of pro-inflammatory cytokines and
effective adaptive humoral and cellular immune responses.67
These innovative approaches have made Ad vectors an ideal
vaccine carrier.
For example, Ebola vaccines based on Ad vectors showed
induction of specific antibody and T-cell responses in clinical trial
subjects.68–70 Notably, HAd26-ZEBOV/MVA-BN-Filo (ClinicalTrials.
gov identifier: NCT04028349) has been shown to be well-tolerated
and produced durable humoral immune responses for more than
a year post vaccination. A vector based on a non-human primate-
derived Ad (ChAd3-ZEBOV) was also well-tolerated in both adults
and children.71,72 In addition, human Ad-based influenza vaccines
that can confer expression of major influenza viral antigens, such
as HA, NP, and M2, have been tested in clinical trials including the
H1N1 and H5N1 (NCT03232567 and NCT00755703).73 A chimpan-
zee Ad vector, ChAdOx1, expressing NP and M1 antigens were
also designed and used in two phase I trials (NCT01818362 and
NCT01623518).74,75 Ad-mediated human immunodeficiency virus
(HIV) vaccines that individually confer expression of the HIV-1
genes gal, pol, and env (HAd5-gag, HAd5-pol, and HAd5-Nef,
respectively) have also been developed and tested.76–79 However,
these trials did not reveal efficacious vaccination. At the time of
this review, no Ad-based HIV vaccine has been proven successful.
The global COVID-19 pandemic, which is caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is
currently the most threatening public health emergency. At the
time that this review was written, SARS-CoV-2 has resulted in more
than 100 million infection cases with more than 2 million deaths
worldwide. In response, multiple vaccine strategies have been
under development. An HAd5-based vaccine that delivers the
SARS-CoV-2 spike glycoprotein was launched in a phase I clinical
trial with 108 participants. Thus far, outcomes showed rapid
humoral and T-cell responses after 14 days post vaccination in
most participants, with no serious adverse events.80 A phase II
clinical trial with a group of 508 participants to evaluate its efficacy
has recently begun. In addition, a phase I/II clinical trial to evaluate
the efficacy of a SARS-CoV-2 vaccine based on the chimp-derived
ChAdOx1 capsid is also underway (NCT04324606).81 Preliminary
data demonstrated that ChAdOx1-nCoV-19 treatment induced
both humoral and cellular immune responses against SARS-CoV-2,
with NAbs in 91% of participants after a single dose and 100%
response after a booster dose.
rAds have also been used to deliver vaccines for cancer
prevention. The overall strategy for immunizing against tumor
cells is to induce the expression of tumor-associated antigens
(TAA) and/or oncolytic processes that promote antitumor immune
responses via Ad-mediated gene delivery. Currently tested
antigens include prostate-specific antigen for prostate cancer
(NCT00583752 and NCT00583024), MAGE-A3 for solid tumor,
human papilloma virus (HPV) E6/E7 for HPV-associated cancers
(NCT02285816, NCT02879760, and NCT03773744), and carcinoem-
bryonic antigen (CEA) for colorectal and pancreatic cancers
(NCT03329248 and NCT03387098). A non-human-derived AdOx1
was employed to deliver the oncofetal TAA, 5T4, to immunize
against prostate cancers (NCT03815942 and NCT02390063). Using
HAd5 vectors to express a combination of TAAs, such as CEA+
brachyury+MUC1 and CEA+ brachyury+mucin 1 (MUC1)+
Her2 are also used to promote cancer vaccination.82
Anticancer therapy. To date, various approaches using Ad
vectors to specifically kill tumor cells have been developed and
tested in clinical trials (Table 1). The early generation of Ad vector-
based anticancer therapies mainly relied on replication-defective
vectors for their immunogenic properties to deliver tumor
repressor, cytotoxic, or immune-regulating genes to induce tumor
cell death and antitumor immune responses.
i. Delivery of suicide genes. Based on the well-established fact
that many tumor types display dysfunction in the p53 tumor
repressor pathway,83 Ad vectors have been engineered to induce
p53 expression to cause cell-cycle arrest and apoptosis in tumor
cells.84,85 However, not all tumor types lack p53 function. Other
applications for Ad vectors in anticancer therapy have been tested
in the targeted expression of pro-drug-converting enzymes to
achieve tumor cell killing. For example, the enzyme purine
nucleoside phosphorylase (PNP) converts the pro-drug fludara-
bine monophosphate (F-ara-AMP) into fluoroadenine, which
confers cytotoxicity to proliferating cells. A dose-escalation phase
I trial to treat patients with advanced tumors was conducted to
test the efficacy of an Ad vector encoding Escherichia coli PNP (Ad/
PNP), followed by intravenous administration of F-araAMP
(NCT01310179).86
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The herpes simplex virus thymidine kinase (HSV-TK) can convert
the pro-drug ganciclovir (GCV) to a cytotoxic nucleotide to
selectively kill dividing cells. In 2004, the first randomized,
controlled clinical trial with the non-replicable Ad HSV-TK/GCV
(AdHSV-TK/GCV) gene therapy was carried out (NCT00005025).87
Since then, Ad-TK vectors have been applied in multiple clinical
trials around the world for treating numerous types of solid tumor
cancers. In 2006, a phase I/II clinical trial was conducted with an
Ad-TK vector under the control of the Rous sarcoma virus long
terminal repeat (LTR) promoter (Ad-RSV-TK) to treat prostate
cancer (NCT01913106).88 Another phase I/II trial used an Ad vector
to express TK with the bone-specific osteocalcin promoter to treat
patients with hormone-refractory prostate cancer exhibiting
metastasis to the bone.89
Cytosine deaminase (CD) can convert the pro-drug 5-
fluorocytosine (5-FC) to toxic 5-fluorouridine (5-FU), which is
further processed in cells to 5-FUTP and 5-FdUMP. These
products cause a blockage of thymidylate synthase and
subsequent damage to DNA. The HAd5-CD/TKrep vector, which
contains the CD/HSV-TK chimeric enzyme transgene, showed
long-term effectiveness when systemically delivered along with
5-FC and GCV, and was used in conjunction with intensity-
modulated radiotherapy (IMRT) (NCT00583492).90 A modified
version of this treatment (HAd5-yCD/mutTK(SR39)rep-ADP),
which delivers a yeast CD fused to a mutated TK enzyme and
the Ad death protein (ADP) showed promise in a phase I clinical
trial for advanced pancreatic cancer (NCT02894944).91 A variant
of this vector, HAd5-yCD/mutTK(SR39)rep-hNIS, also co-delivers
a transgene encoding the human sodium iodide transporter
(hNIS) to enable imaging of tumors to monitor viral spread and
efficacy by single photon radionuclide computed tomography
(SPRCT) and positron emission tomography.92 Another vector
that was designed by the same research group also harbors the
pro-inflammatory cytokine IL-12 to induce an antitumor
immune response.93 Currently, two clinical trials using this
strategy to treat prostate and pancreatic cancer are ongoing
(NCT02555397 and NCT03281382, respectively).
ii. Delivery of immuno-regulatory genes. Ad vectors can also
be armed with immune-regulating genes to stimulate anti-
tumor immune responses in the patient. Intrapleural adminis-
tration of Ad-delivered interferon (IFN)-β or IFN-α-2b to the
lungs have been proven to be safe treatments for malignant
pleural mesothelioma.94,95 Most recently, treatments using Ad-
IFN-α-2b in combination with celecoxib and gemcitabine are
being actively tested in a phase III trial (NCT03710876).
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
is known to induce activation of immune cells to trigger an
antitumor response. Replication-competent HAd5/3 chimeric
viruses expressing GM-CSF (Oncos-102, HAd5/3-D24-GM-CSF)
were tested in a phase I clinical trial to target solid tumors.96,97
Since then, Oncos-102 has been tested in a phase I clinical trial,
and in combination with durvalumab and autologous dendritic
cell immunotherapy (DCVAC/PCa) in phase I/II trials for treating
solid tumors (NCT01598129, NCT02963831, and NCT03514836).
CG0070 is also a replication-competent oncolytic Ad vector that
expresses GM-CSF under control of the human E2F-1 promoter
to target bladder cancer. The treatment underwent a phase II
clinical trial (NCT02365818).98 The interim results demonstrate
that CG0070 confers acceptable levels of toxicity and an overall
47% complete response rate after six months for all patients
and 50% for patients with carcinoma in situ.99
CD40 is a cell surface receptor that has also been shown to
prevent cell proliferation and promote apoptosis once it
interacts with CD40 ligand (CD40L). This association stimulates
T-helper 1 immunity via maturation of dendritic cells and
promotion of M2 to M1 macrophage differentiation.100 In most
breast cancer cells, CD40 is overexpressed, permitting the
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cancers. A vector that expresses CD40L under the control of a
promoter containing a hypoxia-response element and an
estrogen response element (AdEHCD40L) showed cancer-
specific killing ability.101 Another Ad vector expressing CD40L
under the hTERT promoter (CGCT-401) was developed to inhibit
tumor growth via oncolysis and apoptosis.102 LOAd703 is an
immuno-stimulatory oncolytic virus developed by the same
research group and uses an HAd5/35 vector to express
trimerized CD40L and 4-1BBL, another peptide known to
enhance immunologic memory and expand natural killer cells
to stimulate innate and adaptive immune responses.103
LOAd703 is currently being tested in phase I/II trials for
pancreatic cancer patients (NCT03225989, NCT02705196, and
NCT04123470).104
iii. Chimeric and tropism-modified oncolytic Ad vectors. Low
expression levels of CARs, the primary Ad receptor on tumor
cells, often results in resistance to infection by CAR-dependent
oncolytic Ad vectors. To further enhance the cancer-selectivity
of Ad vectors, researchers have sought alternative Ad-receptor
interactions. Delta-24-RGD (DNX-2401) is an oncolytic Ad vector
containing a deletion of the conserved region 2 of E1A
(E1AΔCR2) and an insertion of an ACDCRGDCFCG peptide
sequence (RGD-4C) into the HI loop of the fiber knob protein.
The RGD-4C sequence has been shown to bind strongly to αvβ3
and αvβ5 integrins and enhances virus tropism in a CAR-
independent fashion.105 Phase I trials to test these vectors in
recurrent malignant gliomas patients are ongoing
(NCT00805376, NCT01956734, NCT02197169, NCT03178032,
and NCT03896568).106 Another group of oncolytic Ad vectors
that can infect host cells via RGD-4C sequences and indepen-
dent of CAR binding includes ICOVIR-5 and ICOVIR-7. ICOVIR-5/7
clinical trials have been initiated in cancer patients with
advanced metastatic tumors (NCT01864759).107,108
The gene therapy vector, VCN-01, is characterized by its
putative heparin sulfate glycosaminoglycan-binding site (KKTK)
within the fiber shaft replaced by an RGDK motif. The vector
delivers the human glycosylphosphatidylinositol-anchored
enzyme, PH20 hyaluronidase, to promote viral spread in solid
tumor stroma. VCN-01 has been shown to confer antitumor
efficacy in patients with pancreatic cancer, especially when
combined with chemotherapy (NCT02045589, EudraCT: 2012-
005556-42),109 head and neck squamous cell carcinoma
(NCT03799744), and refractory retinoblastoma (NCT03284268).
An HAd5/3 chimeric vector was created by substituting the
receptor binding fiber knob domain of the HAd5 CR2-deleted
vector with the knob domain of serotype 3 (Ad3), which binds
to a tumor cell-enriched Ad3 receptor, circumventing CAR
interaction.110 A phase I clinical trial of HAd5/3-Δ24 was
conducted in patients with recurrent ovarian cancer.111 Many
additional modifications have been made based on this
chimeric Ad vector. For example, HAd5/3-Cox2L-D24 utilizes
the tumor-specific cyclooxygenase 2 gene promoter to control
E1A expression, to further enforce tumor selectivity.112 The
vector design demonstrated safety and extended virus circula-
tion in patients with metastatic and refractory solid tumors. The
Oncos-102 drug mentioned above is also an HAd5/3 chimeric
virus that targets solid tumors.96,97
Another tumor-selective chimeric Ad vector ColoAd1 (ena-
denotucirev), which was directly evolved via facilitating
recombination among an array of serotypes and selecting
highly potent Ad variants under stringent conditions, showed
potent oncolytic activity in colon cancer cell lines (HT29). This
hybrid Ad vector harbors the Ad11p (B group Ad virus)
backbone and has a near complete deletion of the E3 region,
a smaller deletion in the E4 region, and a chimeric Ad3/Ad11p
E2B region.113 ColoAd1 conferred potent and unique tumor cell
killing properties in multiple solid tumors.114 A phase l clinical
trial test the synergistic effect of combining ColoAd1 with
standard chemoradiotherapy has been launched to treat
advanced rectal cancer (NCT03916510). Most recently, two
independent phase I trials using ColoAd1 to express FAP-TAc
antibody, together with an immune enhancer module (CXCL9/
CXCL10/IFNα) (NCT04053283) and anti-CD40 antibody
(NCT03852511), have been initiated for safety validation.
Challenges for Ad vector-based gene therapy. Although different
types of Ad vectors are currently available for different preclinical
applications, extensive study in Ad vector development have
highlighted serious challenges associated with the high world-
wide prevalence of pre-existing immunity against common
human Ad serotypes, including HAd5. The prevalence rates for
NAbs against HAd5 range from 35% in the United States to over
90% in Cote d’Ivoire.115,116 Circulating anti-HAd5 antibodies have
been shown to significantly impair the ability of HAd5 vectors to
transduce target cells and dampen the resultant adaptive immune
responses.117 Moreover, immunogenicity and cellular toxicity
continue to be major obstacles for Ad gene therapy, despite the
fact that Ad vector-based vaccines and oncolytic therapies benefit
from these properties. Therefore, proper control of Ad vector-
mediated host innate immune responses is key for the success of
these approaches.
The future for Ad vectors. To avoid pre-existing immunity against
Ad vectors, several strategies are being employed. First, several
“rare” human serotypes with low seroprevalence, such as HAd2,
HAd26, and HAd35, were identified and developed into vectors to
minimize pre-existing immunity. However, the ability of these
vectors to induce an immune response have been shown to be
less potent compared with most commonly used HAd5.118 In
addition, various non-human Ad vectors were developed from
bovine (BAd), canine (CAd), chimpanzee (ChAd), ovine (OAd),
porcine (PAd), and fowl (FAd) to limit cross-reactive immunity.
Chimpanzee-derived Ad vectors are most widely used, as NAbs
against these in human blood circulation are significantly lower.119
Thus far, more than ten clinical trials using ChAd3-derived vaccine
have demonstrated the safety of such replication-deficient
vectors.120 Moreover, high-capacity HCAd vectors can achieve
long-term transgene expression in vivo, since they have dam-
pened host immune responses against viral proteins that may be
residually expressed.121 To combat contamination by HV, self-
inactivating HVs such as AdTetCre have been developed, in which
a chimeric MerCreMer recombinase is regulated by a TetOn
system to ensure effective elimination of HV.122 In addition to this
advantage, the lack of viral coding sequences in HCAd genomes
expands the cloning capacity to 37 kb, allowing the accommoda-
tion of site-specific nucleases such as zinc-finger nucleases (ZFNs),
transcription activator-like effector nucleases, and clustered
regularly interspaced short palindromic repeats (CRISPR)/
Cas9 systems for genome editing.
AAV vectors: a small vector with huge potential
Structure and genome. AAV was discovered in 1965 by Bob
Atchison as a contaminant of Ad preparations.123 Due to its
dependence on Ad, or any virus that can serve helper function to
complete its life cycle, it is classified as a dependoparvovirus. Despite
not causing any known human diseases, AAVs are remarkably well-
studied in the short 40 years since their discovery. Much of our
knowledge is owed to its relatively simple genome and its capacity to
be experimentally manipulated in cloning plasmids.
As a dependoparvovirus, AAV lacks the essential genes
needed for replication and expression of its own genome.
These functions are provided by the Ad E1, E2a, E4, and VA RNA
genes.124,125 The AAV genome itself, is a single-stranded DNA
that houses four known open reading frames (ORFs) (Fig. 4). The
first ORF encodes the four replication genes (rep), which are
named after their molecular weights: Rep40, Rep52, Rep 68, and
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Rep78.126 The second ORF is the cap gene that encodes for the
three viral capsid proteins, VP1, VP2, and VP3, respectively.126
The third and fourth are nested sub-genomic mRNAs, named the
assembly-activating protein (AAP),127 which is involved in the
shuttling of capsid monomers to the nucleolus where capsid
assembly takes place; and the recently discovered membrane-
associated accessory protein (MAAP),128 whose function is not
completely understood. The 4.7-kb genome is flanked by 145-nt
ITRs on both ends of the genome (Fig. 4). The ITRs serve as self-
priming structures for replication, and provides the signal for
Rep-mediated packaging.129
The AAV capsid is a T= 1, icosahedral, 60-mer capsid formed
at a 1 : 1 : 10 ratio of VP1, VP2, and VP3 subunits, respectively.
The assembled capsid is best characterized by the five-fold axis
of symmetry that forms the face for rep binding and contains
the five-fold pore, where DNA is inserted under rep-mediated
ATPase activity; and the threefold axis of symmetry that is
defined by the threefold protrusions comprising of variable
loop regions V, VII, VIII, and IV.130 These variable loops establish
the main surface epitope for antibody recognition and receptor
binding. There are at least 12 natural serotypes that can be
categorized into five main clades (Clades A–E) found in
primates.131 Its sero-epidemiology is wide-spread and can be
found in 50–80% of the human population, depending on the
geographical region.132 On their own, AAVs are thought to be
non-pathogenic and have yet to be concretely linked to any
human diseases.
Infection pathway. There are more than a thousand AAV
variants, falling within the five primate clades. Despite the
known diversity, our knowledge of AAV’s infection pathway is
based on only a few serotypes. The prevailing understanding is
that serotypes bind to different, or have differential affinities to
an array of primary cell surface glycoprotein receptors and
secondary receptors.133 For example, AAV2 binds heparan
sulfate proteoglycans.134 The identification of universal recep-
tors has been sought after. Such efforts have discovered
transmembrane proteins, such as AAVR that may act to help
AAV traffic through the cell via intracellular vesicles,135
although not all serotypes turn out to be dependent on AAVR
for transduction.136
Upon binding to the cell surface, clathrin-mediated endocy-
tosis is triggered. The AAV particle is then trafficked in
endosomal vesicles and are transported through late endoso-
mal and lysosomal compartments. Due to the low pH
environments of these vesicles, the capsid undergoes a
conformational change to expose the VP1/2 domains.137
Through a mechanism that is not entirely understood, the
VP1-unique region, which contains a phospholipase domain
escapes the endosome or lysosome compartment, and is then
shuttled into the nucleus via nuclear localization signals found
on VP2. Once within the nucleus, the AAV genome undergoes
second-strand synthesis to form the double-stranded genome
configuration required for gene transcription. In addition, the
ITRs confer intra- and inter-molecular recombination to form
circular dsDNA species or concatemerized genomes.138 This
establishes stability for the AAV genome in an epichromosomal
state. Cell culture evidence and in vivo characterizations have
suggested that the wild-type AAV can integrate into the
genome of the host cell.139–141 The best known integration
site in the human genome is a position in chromosome 19
called AAVS1.140 Although, genomic insertion is likely opportu-
nistic with no general hotspots for wild-type AAV integration
that is well-accepted.
AAV as a vector for gene therapy. The vector genome. Samulski
et al.142 first cloned the AAV genome into expression plasmids and
found that transfection of these plasmids into mammalian cell
lines in the presence of Ad could produce infectious viruses.
Further engineering of recombinant AAV (rAAV) demonstrated
that packaging of transgenes could be achieved by gutting the
genome, save for the ITR elements, and replacing it with any
promoter and gene of interest. The first demonstration of an AAV
vector used in humans was performed in 1995 and involved the
delivery of the cystic fibrosis transmembrane regulator (CFTR)
gene packaged with the AAV2 capsid (rAAV2-CFTR), into a patient
with cystic fibrosis.143 Since this first demonstration, multiple
vector designs have been reported. The design of vectors in a way
is an art form, the reasons for which is manifold. The main
consideration for AAV vector design is that the wild-type genome
is ~4.7 kb in size. Thus, vectors based on them are irrevocably
limited to a ~5 kb capacity. All components needed for proper
expression therefore need to be abbreviated/truncated/minimized
to fit into the small capsid. Alternatively, strategies that exploit ITR-
mediated recombination have produced dual-vector systems that
can express “oversized” transgenes, by way of transcript splicing
across intermolecularly recombined ITRs from two complementary
vector genomes.144–146 Other means of promoting vector-size
expansion through vector recombination by homology,147 RNA
trans-splicing,148 or protein “trans-splicing” via split intein
designs149,150 have also been developed.
The promoters used in AAV vectors, also known as regulatory
cassettes, to drive transgene expression are also an important
aspect of vector design. As contemporary AAV serotypes or
engineered capsids have the capacity to transduce multiple
tissue/cell types, cell-type-specific transgene expression is by and
Fig. 4 Schematic of the AAV genome and sites used for PCR screening. The AAV genome comprised four known open reading frames, rep
(green), cap (salmon), MAAP (orange), and AAP (yellow). The rep and cap ORFs encode four and three isoforms, respectively. Transcription is
driven by the viral P5, P19, and P40 promoters (arrows). The genome is flanked by inverted terminal repeat (ITR, cyan) sequences
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large controlled at the level of gene transcription. Designing
tissue-specific promoters is the main approach for improving on-
target tissue expression. In addition, not only do regulatory
cassettes need to be tissue-specific, they must be powerful
enough to confer therapeutic levels of transgene expression. For
example, the use of muscle-specific regulatory cassettes based on
the muscle creatine kinase gene has been employed for muscle
gene therapy treatments,151 such as Duchenne muscular dystro-
phy (DMD) and limb-girdle muscular dystrophy (LGMD). To meet
the challenges of the small packaging size, bidirectional vectors
have also been employed for delivery of dual therapeutic gene
cassettes. An example of this is the bidirectional chicken β-actin
ubiquitous promoter that drives the simultaneous expression of
the hexosaminidase α- and β-subunits of the HexA enzyme, the
two respective genes involved in Tay-Sachs and Sandhoff
diseases.152
Other non-promoter vector design strategies to control
transgene expression exploits the host cell’s response to foreign
pathogens. A standing challenge for AAV-mediated gene therapy
is how innate immunity plays a role in muting transgene
expression. There is evidence that Toll-like receptor 9 (TLR9)
activation and MyD88 can be activated by the presence of
unmethylated CpG dinucleotides.153 One straightforward way to
circumvent this challenge is to deplete the vector genome of
CpGs by codon optimization and mutation of promoter ele-
ments;153 although, overall expression can be affected.154,155
Other methods for reducing the activation of the immune system
is to employ the cell’s own RNA interference machinery to inhibit
expression in antigen-presenting cells (APCs) by inserting binding
sites for microRNAs (miRNAs) that are highly expressed in these
cell types,156 such as miR142, into the vector genome. This
approach effectively eliminates MHC class I-mediated antigen
presentation in APCs, hence suppressing CD8+ T-cell activation.
157–159 Alternatively, designs to include DNA sequences that are
derived from human telomeres have been reported to inhibit TLR9
activation and reduce rAAV-associated immune responses.160
One frontier that has yet to be fully explored is the rational
engineering of ITR regions.161 Currently, the only widely used
modification to this essential element is to make one ITR
unresolvable during replication. By mutating one of the ITRs so
that Rep can no longer nick the terminal resolution sequence, a
double-stranded genome is packaged into capsids, yielding
vectors termed “self-complementary” AAVs (scAAVs).162,163 This
modification allows for the bypass of second-strand synthesis, the
rate-limiting step for rAAV transduction. The scAAV platform
significantly enhances transduction onset and efficiency. The
drawback is that the maximum genome size is effectively halved,
restricting the packaging limit of the vector. In addition, scAAV
genomes can trigger a stronger innate immune response to the
transgene compared to single-stranded vectors.164–166 Aside from
manipulating how the AAV genome is packaged, is has long been
evidenced that the ITR harbors promoter function.167 The extent
by which ITRs can impact transgene expression is not well-studied.
However, new evidence suggests that the ITRs of different
serotypes can confer differential promoter activity.168 Further-
more, there is evidence that the ITRs can produce transcripts on
the minus strand, independent of a classical promoter on the
reverse strand.169,170 The result of such action is the formation of
double-stranded RNAs, which can trigger the host innate immune
system. Our lack of full understanding for the AAV vector
transduction pathway, and ways in which the ITRs can serve to
impact vector genetic fate, has limited our ability to modulate the
very last viral elements still residing in current vectors used for
gene therapy.
Capsids. The advancement of AAV to expand the capsid toolbox
has been the focal point for improving AAV vectors in recent
years. The capsid is not only critical for the recognition of cell
surface proteins that impact tissue/cell tropism,133 but also serves
as the epitope for antibody recognition,171 functions as the
substrate for phosphorylation (either prior to or during viral egress
from the late endosome for proteasomal degradation),172 and has
been shown to remain bound to the genome to impact second-
strand synthesis and transcription in a cell-type-specific man-
ner.173,174 As AAVs cannot be easily engineered with capsid
proteins from other non-related viruses to yield chimeric vectors
with modified properties (pseudotyped), work in the past two
decades has focused on developing new capsids with improved
properties via alternative approaches. There are currently four
main methods for capsid discovery: (1) vectorization of AAV
capsids from natural isolates; (2) rational design of capsids using
pre-existing capsid as scaffolds; (3) directed evolution of capsid
libraries generated by error-prone PCR and/or shuffling of pre-
existing capsids with desired properties; and (4) in silico
approaches involving the use of computational tools to design
novel capsids not observed in nature. We will highlight some of
the milestones met in these four categories.
i. Natural isolates. Serotypes AAV1 and AAV2 were first
discovered from tissue culture. Afterwards, AAV serotypes were
isolated from a range of mammalian species and tissue types.
Between 1965 to 2001, only a handful of AAVs, mostly from
human clinical samples, were derived from viral isolates,
vectorized, and tested. Following these efforts, which demon-
strated that each serotype had unique tropism profiles, larger
studies to isolate AAVs from human and non-human primate
tissues were accomplished by using PCR- amplification of proviral
cap sequences. At the end of 2009, more than a hundred variants
across six different clades were discovered.131,175,176 Although
only a few research groups continue to screen natural variants as
potential gene therapy vectors, they are still the predominant
capsids used in clinical studies today.
ii. Rational design. The engineering of pre-existing capsids by
rational design is an efficient means of developing new capsids
with specific properties.177 Rational design approaches have
produced some capsids with beneficial characteristics that are
improved over natural variants. Such strategies began with the
grafting of peptide sequences known to bind surfaces of target
tissues onto the surface of the capsid.178 The latest achievement
using such a strategy was the development of bone-homing
capsid named AAV9.DSS-Nter.179 However, the generation of
functional capsids through these means are in general difficult.
Part of the reason behind this difficulty is that the AAV capsid and
it’s role during the viral life cycle is not completely understood, i.e.,
changes on the capsid may theoretically improve binding of AAV
to specific cell receptors, but may negatively impact other aspects,
such as vector production or cellular trafficking.
iii. Directed evolution. Iterative selection of randomly mutated
capsids in cell culture or in animals, coupled with next-gen
sequencing strategies have given researchers a manageable
means of developing new capsids with defined properties.177
Randomized mutations can be achieved by error-prone PCR180 or
by the generation of chimeric capsids (capsid shuffling) from the
primary sequences of pre-existing serotypes.181–183 The most
noteworthy examples of evolved capsids are derived from
platforms based on the insertion of short, randomized peptide
sequences onto the threefold protrusions, which are highly
amenable for capsid manipulation.184 Among the first in this class
of capsids are AAV2.7m8 and AAVPHP.B.185,186 The AAV2.7m8
capsid was derived by the insertion of a random seven-amino acid
sequence into loop VIII of the AAV2 capsid and iterative rounds of
random mutagenesis and selection of positively transduced
photoreceptor cells. The development of high-throughput
sequencing approaches in the early 2000s marked not only the
capacity to profile the transcriptome and epigenetic marks on a
whole-genome scale but also allowed for AAV investigators to
expand screening depth to test millions of variants at once.
Unfortunately, these screening methodologies are limited in that
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they can only evolve capsids that perform well in the systems they
are screened in. For example, the discovery of AAV.PHP.B, which
was screened for its ability to traverse the blood–brain barrier
(BBB) in C57BL6 mice, produced a capsid that exhibited strain-
specific differences.187 Nonetheless, this work was able to reveal
the species- and strain-dependent LYS6A gene as the critical
receptor that permits AAV.PHP.B to traverse the BBB.188 Additional
capsids have thus far been evolved that do not rely on Lys6A host
expression, such as AAV-F.189 Further improvements to these
methodologies are ongoing and they offer a rapid means of
developing new capsids for specific targets.
iv. In silico approaches. The use of computational approaches
to develop novel AAV capsids for gene therapy is a relatively
new concept.177 Within the past few years, this approach is best
exemplified by the discovery of Anc80, a capsid whose sequence
is predicted to be the “ancestral” capsid by phylogenetic
connectivity between contemporary capsids. Importantly,
Anc80 has shown strong tropism to the mouse liver, muscle,
retina, and cochlea.190,191 The evaluation of germline endogen-
ous viral elements (EVEs) also represent attempts to reconstruct
novel ancestral capsids with the potential for vectorization.192
By using bioinformatics approaches to identify and analyze EVEs
among several marsupial species, “fossilized” viral integration
events within host DNA have been uncovered. Recently, the
single-amino acid substitution across the entire AAV2 cap ORF in
combination with machine learning approaches have been used
to further increase the depth of variants that can be queried for
improved vector performance. The use of machine learning
approaches truly represents a new frontier in the gene therapy
field. Computer-assisted structure–function analyses has great
potential for producing capsids sequences not seen in nature.
These tools are developed to consume and integrate large
amounts of data on the performance of capsids with single or
multiple amino acid changes (production and transduction
efficacies), to ultimately derive novel capsids with desired
properties. These means can potentially bypass the iterative
steps required for directed evolution and can overcome the trial
and error process attributed to rational design approaches.
Machine-guided strategies have already demonstrated their
utility by uncovering a previously unknown ORF encoding for
the MAAP gene.128
The nuances of AAV vector biology. AAV vectors have been
universally recognized as versatile vectors for gene therapy. Much
of this is owed to their wide-ranging tropism profiles, even by the
contemporary serotypes. As a result, most AAV vector platforms
have been developed to target diseases of the central nervous
system, the eyes, liver, heart, and muscle. Similar to their wild-type
counterparts, AAV vector genomes undergo circularization via ITR
recombination to form stable and persistent episomal configura-
tions that can be detected well beyond 10 years following
administration in non-dividing, terminally differentiated cell
populations.193–195
Compared to other current viral vectors, rAAVs are accepted as
the least immunogenic, with much less vector-related toxicity. In
contrast to Ad vectors, AAVs are ideal for their lack of transgene
immunity when expressing self-antigens and confer relatively low
innate immunity and viral immunity within a broad dose
range.196,197
One final nuance for AAV vector research is that assessing AAV
vector performance is not ideal with in vitro models. Typically,
transduction of rAAVs in vivo does not tend to reflect what is
observed in vitro. Furthermore, the field is increasingly aware that
results gleaned from small animal models may not necessarily be
reproduced when tested in human trials. This failure has led to the
necessity for researchers to carry out studies in non-human
primate models such as cynomolgus or rhesus macaques before
clinical trials are realized.
Production platforms. Although AAV-based vectors have shown
great promise as gene therapy drugs, one of the limitations for
rAAVs is achieving scalable and economical production of vectors
that are free of impurities. Since the initial vectorization studies to
produce single-strand rAAVs in the 1980s, clinically relevant
advancements in AAV vectorology have been intermittent. The
scAAV platform is sometimes referred to as the second generation
of rAAVs, but they were developed nearly 20 years ago. In
contrast, vector production platforms have undergone multiple
advancements. Since both single-stranded AAV and scAAV vectors
are absent of all viral components save for the ITRs, the universal
strategy for different production schemes is to achieve optimal
trans expression of obligatory factors required for packaging AAV.
Knowing that impurities continue to be a burden for generating
high-quality vectors, efforts to streamline and improve vector
yields have been the focus for improving manufacturing practices
in recent years. Currently, vector production schemes for clinical
use have yet to adopt strategies that are completely cell free.
Triple transfection: HEK293. Preclinical/research-grade AAVs are
still predominantly produced by the standard triple-transfection
method in HEK293 cells. Typically, this employs the co-transfection
of the cis plasmid containing the transgene cassette of interest,
flanked by ITRs; the trans plasmid, which houses the rep and cap
genes, and the Ad helper plasmid, which provides the E2a/b, E4,
and VARNA genes. As HEK293 cells are transformed by Ad,198 they
express the essential E1a and E1b genes. These cells are typically
incubated as semi-adherent cultures and reach maximum produc-
tivity at 2–3 days post transfection, losing viability overtime.199
Mammalian stable cell lines. Stable cell lines that constitutively
express vector components have been developed to streamline the
production process. These platforms free the need to deliver, for
example, capsid expression cassettes and/or helper genes on a
plasmid. They only require the delivery of the vector genome to be
packaged. Clark et al.200 first developed a HeLa-based producer cell
line in the mid-1990s, by cloning rep/cap and the rAAV vector
genome into an expression plasmid, and then using it to stably
transfect HeLa cells. Such a cell line would only require infection by
wtAd5 to trigger high-yield vector production. One obvious
limitation of this strategy, is that a cell line must be produced for
every vector design. Alternatively, hybrid rAAV/rAd vectors were
developed to deliver both the transgene vector and adenoviral
elements to provide robust rep-cap expression from stably integrated
AAV genes in HeLa cell lines. These platforms yield high-titer vector
for large-scale production needs.201,202 Producer cell lines derived
from A549, a lung-epithelial carcinoma cell line, have also been
developed.203 Other vector-based production methods such as HSV
vectors have been engineered to deliver within them AAV vector
components into baby hamster kidney fibroblast cells (BHK21).204
These platforms are great for production scale-up and enables the
generation of clinical-grade vectors. In addition, the use of stable cell
lines limits the auxiliary components necessary for production and
removes sources of contamination, like adventitious viruses or
plasmid contaminants originating from DNA preparation steps.
Unfortunately, the concern with using immortalized or transformed
cell lines is that the elements that confer their characteristics can be
packaged into the vectors as impurities, raising the possibility of
genotoxicity in the host, as well as potentially harmful carryover
helper viral impurities. Furthermore, unlike the HEK293-based
platforms, these stable cell lines lack E1a/E1b expression and
therefore require replication-competent Ad helper and/or Ad-AAV
(replication-defective) hybrid virus infection. Thus, many methods
have been developed to determine whether potential oncogenes or
transforming factors end up in manufactured AAVs. Most recently,
SSV-seq, AAV-GPseq, and Fast-seq approaches have all been
developed to address the relative abundance of mispackaged
nuclear material that winds up in preparations.205–207
Baculovirus/Sf9. An alternative production scheme to mammalian
cell lines is the use of baculovirus expression vector (BEV) system in
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Spodoptera frugiperda insect cells (Sf9). This involves the generation
of recombinant baculoviruses: one BEV carrying the AAV vector
genome, flanked by ITRs, and in another, the rep and cap genes. The
BEVs are in turn used to infect Sf9 cells. Since the baculovirus
provides helper function,208 a single BEV system in conjunction with
Sf9 cell lines that stably express rep, can be employed for flexible and
high-titer large-scale vector production.209 Interestingly, a report that
vectors produced from Sf9 cells are differentially posttranslationally
modified, as compared to those generated from human- or
mammalian-derived cell lines raised question as to whether
differences in production schemes may impact tropism and
transduction efficacies,210 although further work in this area is
necessary to cross-validate these findings. Nonetheless, BEV/
Sf9 systems exhibit reduced encapsidation of contaminating
DNAs205 and therefore remain an attractive production strategy for
large-scale, clinical-grade vectors.
Therapeutic AAV vectors and commercial availability. To date,
there are have been three AAV-based gene therapy drugs
worldwide that have made it to the commercial market. Although
they symbolize the things to come for these promising platforms,
two major challenges remain: cost of treatment and safety.
Manufacturing represents a third challenge. However, the demand
for these drugs has yet to reach levels in which manufacturing has
created significant bottlenecks. Although manufacturing limita-
tions can still slow clinical trials, most of these drugs are currently
developed towards monogenic diseases, which belong to the
category of rare diseases and the patient population eligible for
trials remains relatively low.
Glybera (alipogene tiparvovec) was the world’s first AAV-based
gene therapy to gain regulatory approval for commercialization
from the European Medicines Agency in 2012.211 Glybera is an
AAV1-based gene therapy that delivered lipoprotein lipase (LPL)
to patients with LPL deficiency.212 It was also infamous for gaining
the moniker of “the world’s first million-dollar drug.” Due to low
demand and its high cost, Glybera was withdrawn from European
markets and has yet to gain approval in other countries.
Altogether, only four patients outside of clinical trials ever
received the drug, three of which payed only €1 to expend the
remaining unused stocks.
Luxturna (voretigene neparvovec-rzyl) was the second AAV
drug that gained commercial approval in 2017—first by the U.S.
Food and Drug Administration (FDA). Luxturna is an AAV2-based
vector that delivers the retinoid isomerohydrolase RPE65,213 the
effected gene in Leber’s congenital amaurosis, which causes
progressive blindness. On its launch, the drug held a price tag of
$425,000 per eye.
Zolgensma (onasemnogene abeparvovec) is the third and the
most recently approved AAV drug, developed for the treatment of
spinal muscular atrophy (SMA).214 It gained approval in the United
States and Japan in 2019, and received approval in the EU in 2020.
Zolgensma is a one-time gene therapy that delivers the survival
motor neuron (SMN1) transgene to replace the non-functional
SMN1 gene mutated in patients with SMA. During its launch, it was
marketed at $2.125 million per dose—currently, the most
expensive medication in the world.
Clinical trials. With the approval of the first AAV-based drugs and
continued promising clinical data across the field, several gene
therapy platforms have sprung forth and are currently under
investigation in the clinic. As a result, there have been over 200
clinical trials based on AAV worldwide. For many trials, enrollment
is limited to only a few individuals and the selection criteria are
many times very restricted. Combined with the fact that many
current gene therapy strategies are presently only developed for
rare diseases, the advancement of these new drugs are slow. The
FDA and National Institutes of Health are now recognizing that the
number of eligible patients is limited and many AAV treatments
are for lethal diseases with no alternative options. Therefore, many
combined phase I/II or II/III trials have been granted. Table 2
summarizes all current AAV-based clinical trials. The following
clinical trials highlight some of the most noteworthy outcomes.
Age-related and diabetic macular degeneration (AMD). ADVM-022
is an intravitreal injection of an AAV vector carrying aflibercept, an
anti-VEGF fusion protein that blocks blood vessel growth and
leakage related to AMD and diabetic retinopathy. What makes this
gene therapy stand out is the use of AAV2.7m8, the evolved
capsid that is strongly tropic to photoreceptors.185 Current phase I
clinical trials aim to assess safety and tolerability of a single
intravitreal injection in patients with AMD, correction of visual
acuity, and the elimination of anti-VEGF rescue injections
(NCT03748784). The most recent and positive outcomes from
patients receiving treatments showed mean best corrected visual
acuity improvements (+6.8 letters) and central subfield macular
thickness reduction (−137.8 μM), indicators of disease reversal.215
Muscular dystrophies. The fight against DMD has a long history
and, thanks to awareness efforts throughout the decades,
groundbreaking research has resulted in successful treatments
of the disease via AAV-based gene therapy.216 DMD is a fatal X-
linked neuromuscular genetic disease that occurs in ~1 in every
3500–5000 males worldwide. DMD is caused by mutation(s) in
dystrophin, a structural gene that provides tensile strength and
integrity to striated muscles, and is one of the largest proteins in
the human body. As a result of many years of work, several groups
have developed platforms with clinical trials currently underway.
SRP-9001 is an AAVrh.74 capsid-based vector that harbors a
shortened form of dystrophin. The discovery of microdystrophin,
whose shortened design was inspired by the mutant form of the
dystrophin gene observed in Becker muscular dystrophy, is the
basis of the vector’s success.217 As AAV is limited in its packaging
capacity, the relatively short transgene allows for packaging of the
transgene along with the striated muscle-specific regulatory
cassette called αMHCK7, a combined α-myosin heavy chain
enhancer and version 7 of the creatine kinase promoter.151 The
treatment confers systemic and robust therapeutic transgene
delivery to skeletal and cardiac muscles. A similar gene therapy
strategy to tackle LGMD (SRP-9003) has also implemented. SRP-
9003 delivers β-sarcoglycan—a gene when missing, causes LGMD
Type 2E. Trials to test these gene therapy platforms are under the
respective clinical trial identifiers NCT03769116 and NCT03652259.
Despite the promise of some DMD gene therapy trials, others
have been met with challenge. SGT-001 is also an AAV vector
packaging microdystrophin. Although clinical outcomes for trials
testing SGT-001 (NCT03368742) showed that 50–70% of muscle
fibers express the therapeutic transgene and conferred a decline
in muscle damage, some patients had adverse effects, where at
least one patient had an immunological response to the gene
therapy.218 Albeit the adversity was resolved, the FDA’s decision to
halt trials are a reflection of its dedication to ensuring that trials
are safe for the patients. Similarly, patients who were systemically
administered with high doses of PF-06939926 (NCT02310763)
experienced transient and/or acute renal impairment, accompa-
nied by activation of the complement system.219
Hemophilia. The gene therapy field for hemophilia, a family of
severe blood clotting diseases, has long had its ups and downs.
The numerous human trials in the mid-1990s to the early 2000s
reflected the diversity of strategies aimed at correcting this blood
clotting disease. In fact, AAVs, retrovirus, and Ad vectors were all
explored. The first AAV-based hemophilia strategies aimed to
target muscle tissues to act as biofactories for expressing factor IX
(F.IX) treat hemophilia B220 showed no toxicity and sustained
transgene presence beyond multiple years post administration.
However, these studies also demonstrated that the therapeutic
dose via intramuscular injections could not be achieved by
muscle-targeted transgene expression without larger vector doses
or clinically impractical injection regimens.221,222 In a milestone
Viral vector platforms within the gene therapy landscape
Bulcha et al.
12
Signal Transduction and Targeted Therapy            (2021) 6:53 
Table 2. A selection of ongoing clinical trials employing AAV vectors
Condition Intervention Sponsor Trial stage Identifier
AADC deficiency AADC Krystof Bankiewicz UCSF Phase I NCT02852213
AADC National Taiwan University Hospital Phase II NCT02926066
Batten disease (CLN2) CLN2 Weill Cornell Phase I/II NCT01414985
Batten disease (CLN6) CLN6 Nationwide Children’s Hospital Phase I/II NCT02725580
MPS-IIIB NAGLU UniQure Phase I/II NCT03300453
Parkinson disease AADC Jichi Medical University Phase I/II NCT02418598
GDNF NINDS Phase I NCT01621581
Neurturin Sangamo Phase I/II NCT00985517
AADC Voyager Phase I NCT03065192
SMA SMN AveXis Phase III NCT03461289
GAN GAN NINDS Phase I NCT02362438
Achromatopsia CNGB3 AGTC Phase I/II NCT02599922
CNGB3 MeiraGTx Phase I/II NCT03001310
Choroideremia REP1 Nightstar Phase III NCT03496012
REP1 Spark Phase I/II NCT02341807
REP1 STZ Eyetrial Phase II NCT02671539
REP1 University of Oxford Phase II NCT02407678
LCA RPE65 Spark Phase III NCT00999609
RPE65 MeiraGTx Phase I/II NCT02781480
LHON ND4 GenSight Phase III NCT03293524
ND4 John Guy University of Miami Phase I NCT02161380
RP (RLBP1) RLBP1 Novartis Phase I/II NCT03374657
Wet AMD Anti-VEGF antibody Regenxbio Phase I NCT03066258
Anti-VEGF protein Adverum Biotechnologies Phase I NCT03748784
X-Linked RP RPGR AGTC Phase I/II NCT03316560
RPGR MeiraGTx Phase I/II NCT03252847
RPGR Nightstar Phase I/II NCT03116113
X-linked retinoschisis RS1 AGTC Phase I/II NCT02416622
RS1 NEI Phase I/II NCT02317887
Crigler–Najjar syndrome UGT1A1 Audentes Phase I/II NCT03223194
UGT1A1 Genethon Phase I/II NCT03466463
FH (homozygous) LDLR University of Pennsylvania Phase I/II NCT02651675
GSD1a G6PC Ultragenyx Phase I/II NCT03517085
Hemophilia A FVIII Shire Phase I/II NCT03370172
FVIII Bayer Phase I/II NCT03588299
FVIII BioMarin Phase III NCT03392974
FVIII Sangamo Phase I/II NCT03061201
FVIII Spark Phase I/II NCT03003533
FVIII UCL Phase I NCT03001830
Hemophilia B FIX Shire Phase I/II NCT01687608
FIX Pfizer Phase II NCT02484092
FIX Pfizer Phase III NCT03587116
FIX Sangamo Phase I NCT02695160
FIX St. Jude Children’s Research Hospital Phase I NCT00979238
FIX UniQure Phase III NCT03569891
FIX UCL Phase I NCT03369444
FIX Freeline Therapeutics Phase II/III NCT03641703
MPS-I ZFN1, ZFN2, IDUA donor Sangamo Phase I NCT02702115
MPS-II ZFN1, ZFN2, IDS donor Sangamo Phase I NCT03041324
MPS-IIIA SGSH LYSOGENE Phase II/III NCT03612869
MPS-VI ARSB Fondazione Telethon Phase I/II NCT03173521
OTC deficiency OTC Ultragenyx Phase I/II NCT02991144
A1AT deficiency A1AT UMMS Phase I NCT00377416
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trial, delivery of AAV-F.IX to the liver showed successful transduc-
tion to human hepatocytes. However, this result was also met by
immunological responses to capsid protein and subsequent
decline in circulating F.IX levels, showing that immunotoxicity
was a critical barrier for therapeutic vectors.223 Nearing the end of
2017, AAV delivery of FVIII to the liver with AAV5224 and a high-
activity F.IX variant (F.IX-Padua), which exhibits eight times more
activity than the normal protein, also targeting the liver,225 were
demonstrated in trials. There are currently at least 12 ongoing
clinical trials that are being pursued by 5 pharmaceutical
companies. Many of these are in phase II/III stages and thus show
promise for commercialization, namely fidanacogene elaparvovec,
developed to treat hemophilia B; SPK-8011, a gene therapy for
hemophilia A; Valrox (valoctocogene roxaparvovec or BMN 270), a
gene therapy to treat hemophilia A; and AMT-061, a gene therapy
for hemophilia B, are currently being tested in phase III clinical
trials (NCT03392974 and NCT03569891). FLT180a is also in a phase
II/III study with hemophilia B patients in the U.K (NCT03641703).
X-Linked myotubular myopathy (XLMTM). Recently, a clinical trial
involving high-dose administration of AT132 (NCT03199469), an
investigational gene therapy product candidate for XLMTM, led to
the deaths of three patients who had progressive liver dysfunc-
tion, characterized by hyperbilirubinemia.226–228 The patients were
notably of older age, heavier weight, and had prior histories of
hepatobiliary disease. Nevertheless, this unfortunate outcome
signals how important it is to determine safe, therapeutic doses. It
is a continuing challenge for researchers and clinicians to advance
their therapeutic strategies to human patients, knowing that there
are risks involved. Still, these trials are very much needed.
Challenges. The growing number of clinical trials using rAAVs is a
positive sign that these vector-based gene therapies hold a lot of
promise; yet, there are still quite a lot of challenges that the field
has yet to address. Immunogenicity towards the vector remains
the largest challenge for AAV-based gene therapies. In fact, the
immune system will always be a major barrier for any gene
therapy approach. Thus far, adaptive immunity to the capsid and
the foreign transgene represents major factors for decreased
efficacies. Although the single administration aspect and sustain-
ability of AAV gene therapy mean that the need for redosing can
be avoided, patients that have been exposed to AAV serotypes
that a gene therapy is based on, will have a high-chance of
presenting NAbs against the vector capsid.171 The goal of
discovering new capsids seeks to partially address the presence
of NAbs against serotypes commonly found in populations. For
circumstances where tailoring the vector platform to the patient is
not possible, plasmapheresis is a plausible means of removing
anti-AAV antibodies from the bloodstream229 or pre-treatment
with IgG-cleaving endopeptidases such as imlifidase (IdeS) can
nonspecifically reduce IgG antibodies from the sera of patients.230
IdeZ, a homolog of IdeS, isolated from Streptococcus zooepidemi-
cus, demonstrated efficacious removal of capsid NAbs in non-
human primate (NHP) studies.231 Adaptive immunity towards the
transgene may be more straightforward to address. As mentioned
above, detargeting from professional APCs, such as dendritic cells
with tissue-specific promoters and the design of miRNA binding
sites for miR142 to silence transgene expression, can circumvent
adaptive immunity.157–159
Mechanisms for innate immunity have been well-described in
response to viruses, but exploration of innate immune response
towards AAV vectors is understudied. Serotype-specific responses
have been observed and can be directly addressed. Namely,
differences in receptor binding between AAV2 and AAV8, whereby
AAV2’s preference for heparin proteoglycans may confer higher
T cell response, may lead to strategies to mitigate immunity via
rational design.232 In addition, evidence is accumulating for the
possibility that the AAV vector genome can elicit an innate immune
response,233 necessitating an area of research that is critically
needed. TLR9 detection of methylation-free CpG dinucleotides is
one means by which cells can identify foreign DNA. Other foreign
DNA- and RNA-sensing mechanisms, involving RIG-I (Ddx58), CGAS
(Mb21d1), and STING (Tmem173), may also play roles.234
Finally, a challenge that must be confronted is managing the right
treatment doses, which may be at the heart of the strong
Table 2. continued
Condition Intervention Sponsor Trial stage Identifier
CMT1A NTF3 Nationwide Children’s Hospital Phase I/II NCT03520751
DMD Microdystrophin Nationwide Children’s Hospital Phase I/II NCT03375164
Mini-dystrophin Pfizer Phase I NCT03362502
Microdystrophin Solid Biosciences Phase I/II NCT03368742
Microdystrophin Sarepta Therapeutics Phase II NCT03769116
LGMD, type 2E LGMD2E Sarepta Therapeutics Phase I/II NCT03652259
Dysferlinopathy DYSF Nationwide Children’s Hospital Phase I NCT02710500
HIV infections PG9 antibody International AIDS Vaccine Initiative Phase I NCT01937455
VRC07 antibody NIAID Phase I NCT03374202
Pompe disease GAA Actus Therapeutics Phase I/II NCT03533673
GAA University of Florida Phase I NCT02240407
X-linked MTM MTM1 Audentes Phase I/II NCT03199469
A1AT α1 antitrypsin, AADC aromatic l-amino acid decarboxylase, AGTC Applied Genetic Technologies Corporation, AMD age-related macular degeneration, ARSB
arylsulfatase B, CLN2 neuronal ceroid lipofuscinosis type 2, CMT1A Charcot–Marie–Tooth disease type 1A, CNGB3 cyclic nucleotide-gated channel-β3, DMD
Duchenne muscular dystrophy, DYSF dysferlin, FH familial hypercholesterolemia, FVIII factor VIII, G6PC glucose-6-phosphatase catalytic subunit, GAA α-
glucosidase, GAN gigaxonin, GDNF glial cell line-derived neurotrophic factor, GSD1a glycogen storage disease type 1a, LCA Leber congenital amaurosis, LDLR
low-density lipoprotein receptor, LHON Leber hereditary optic neuropathy, mAb monoclonal antibody, MPS mucopolysaccharidosis, MTM myotubular
myopathy, NAGLU N-α-acetylglucosaminidase, ND not disclosed, ND4 NADH-ubiquinone oxidoreductase chain 4, NEI National Eye Institute, NIAID National
Institute of Allergy and Infectious Diseases, NINDS National Institute of Neurological Disorders and Stroke, NTF3 neurotrophin 3, OTC ornithine
transcarbamylase, REP1 RAB escort protein 1, RLBP1 retinaldehyde-binding protein 1, RP retinitis pigmentosa, RPE65 retinal pigment epithelium-specific 65 kDa
protein, RPGR retinitis pigmentosa GTPase regulator, RS1 retinoschisin 1, SGSH N-sulfoglucosamine sulfohydrolase, SMA spinal muscular atrophy, SMN survival of
motor neuron, UCL University College London, UCSF University of California San Francisco, UGT1A1 UDP glucuronosyltransferase family 1 member A1, UMMS
University of Massachusetts Medical School, VEGF vascular endothelial growth factor, ZFN zinc-finger-containing protein.
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immunological responses and subsequent toxicities seen in recent
trials. Although AAV-based gene therapy for SMA has been proven
to be safe, interpatient differences may impact the response. In a
preclinical study in piglets and non-human primates, where
supraphysiological transgene expression was achieved, propriocep-
tive deficits and ataxia was observed, and was attributable to high
transduction of the dorsal root ganglia (DRG) and subsequent
toxicity.235 In fact, a recent meta-analysis of 33 non-clinical studies
encompassing 256 NHPs showed that the majority of animals
administered via cerebrospinal fluid (CSF) exhibited DRG patholo-
gies.236 Using miRNA-detargeting can reduce toxicity.237 These
studies and others indicate that further evaluation of the appropriate
routes of administration, capsid choice, and vector genome designs
are still needed, even for approved drugs.
The future for AAV vectors. Despite some setbacks, AAV vectors still
hold huge promise for correcting disease. Now with the preclinical
successes seen with CRISPR/Cas systems, which allow programmed
editing nearly anywhere within the genome, the potential for AAVs
seems limitless.238 However, every approach has their downsides.
AAV vectors have always been considered relatively safe, yet recent
demonstration that AAV vector genomes carrying CRISPR compo-
nents can integrate into the host cell genome at the site of double-
strand breaks239 has raised concerns over their efficacies and long-
term safety profiles. In fact, in a 10-year follow-up study in six dogs
receiving gene therapy vector for F.VIII, vector genomes were found
to be stably integrated into the host genome and has re-raised
concerns for oncogenic integration of AAV.240 Despite the overall
positive safety track record for AAV treatments in humans, continued
efforts in gauging the long-term and short-term safety for AAV
vectors are certainly warranted.
Lentivirus vectors: a robust vector for genetically modified cell
therapies
Structure and genome. Lentiviruses constitute a genus of the
retroviridae family. Retroviruses are spherical, enveloped, single-
stranded RNA viruses that are ~100 nm in diameter.241,242 The
lentiviral particle encapsidates two sense-strand RNAs that are
bound by nucleocapsid proteins. The particle also contains reverse
transcriptase, integrase, and protease proteins. Retroviruses can be
classified into simple or complex viruses, based on their genome
organization. Gammaretroviruses are an example of simple retro-
viruses, whereas the HIV-1, a lentivirus, is an example of a complex
retrovirus. The 9.7 kb HIV-1 genome is flanked by 5′- and 3′ LTRs,
which are integral to viral genome replication. The LTR is composed
of U5 and U3 sequences that are unique to the 5′ and the 3′ termini
of the viral genome, respectively, and R, which is a common
sequence at both ends. The cis-acting sequence, also known as psi,
resides just outside of the LTR and is pivotal for signaling viral
genome encapsidation.243,244 Retroviruses have common essential
core protein genes, such as gag, pol, and env. Although the gag
gene encodes for the protective capsid and matrix proteins, the env
gene carries information for transmembrane and envelope glyco-
proteins that dictate the virus’ cellular tropism.245 Reverse tran-
scriptase and integrase are transcribed from the pol gene. As part of
an intricate regulatory machinery that facilitates viral replication,
lentiviruses have additional genes called tat and rev. Tat supports
transcriptional activation and RNA polymerase II elongation by
binding adjacently to the LTR.246 Rev orchestrates nuclear export of
spliced and un-spliced viral RNA by binding to a motif in the env
gene region.247 Lentiviruses, such as HIV-1, have an additional set of
auxiliary genes (vif, vpr, vpu, and nef), which elevate the viral titer and
pathogenesis of the virus.248,249
Infection pathway. The entry of infectious lentiviral particles to
the host cell is mediated by interactions between glycoproteins
anchored on the outer envelope and a specific cell receptor.
Successful binding to cell surface receptors prompts a series of
events that lead to the fusion of the viral particle lipid bilayer and
the cell, and subsequent unloading of the viral genetic cargo into
the cytoplasm.250–252 Lentiviral DNA integrates into the host
genome in a non-random manner with preference for transcrip-
tionally active sites.253–255
Lentiviruses as vectors in gene therapy. Lentiviral vectors have
several features that make them amenable to transgene delivery
for therapeutic purposes. Lentiviral vectors are integrating vectors
that permit long-term transgene expression. They have a
packaging capacity of up to 9 kb.256 High-level expression of
multiple genes may be a requisite for achieving a therapeutic
outcomes for certain diseases. Employing two separate vectors
carrying co-dependent transgenes may not be an optimal
solution, as successful transduction of multiple viral vectors to
the same cell is not efficient. Lentiviral vectors are demonstrated
to have the ability to express multiple genes from a single
vector.257–259 Lentiviral vectors can transduce postmitotic and
quiescent cells, whereas other retrovirus-based platforms, such as
gammaretroviral vectors, require active cell division for successful
infection. Although quiescent cells are mostly recalcitrant to
infection, partly as a result of the innate immune response,260
stimulation of mitotic entry can facilitate viral transduction.261–264
Depending on the viral vector design, lentiviral vectors elicit
relatively weak immune responses.265,266
Lentiviral vector systems that are derived from the HIV-1 virus
have evolved through the years. These advancements have been
made in part to mitigate the potential risks associated with the
virus that the platform is based on. One obvious safety
consideration in designing a lentiviral vector system for gene
therapy is the unintended generation of replication-competent
provirus. The first generation of HIV-1-based vectors retained most
of the viral genome within the trans packaging construct,
including the viral core, regulatory protein coding sequences,
and accessory regulatory genes.256 In the three-plasmid design to
generate vector, the env gene is replaced by the glycoprotein of
vesicular stomatitis virus (VSV-G) and is separately provided in
trans by a second plasmid. In this way, pseudotyping the viral
particle with VSV-G facilitates viral entry independent of its native
host cell receptor. The therapeutic transgene is provided in a third
plasmid construct along with the cis-acting elements that confer
viral encapsidation. The second generation of safer lentiviral
vectors are devoid of vif, vpr, vpu, and nef auxiliary genes, which
promote viral proliferation and infection.267 To limit the formation
of unintended replication-competent provirus, third-generation
vectors that lack the tat and rev regulatory genes in the packaging
construct were developed (Fig. 5).268 The rev gene, which is
required for replication, is supplied in trans, creating a conditional
packaging platform. The safety profile of the third-generation
lentiviral system is further improved by deleting part of the 3′-LTR,
which contains the TATA box and transcription factor-binding
sites; thus, creating a vector packaging system that is self-
inactivating.269
Additional modifications have been made to improve the
expression and transduction efficiency of lentiviral vectors. Incorpor-
ating transcriptional regulatory elements, such as a central
polypurine tract (cppt) and a matrix attachment region (MAR) in
the cis expression vector augments viral transduction.270 Inclusion of
scaffold attachment regions from the β-interferon gene into the
vector design enhances the expression of vector transgenes in
quiescent T cells.271 In addition, incorporating woodchuck hepatitis
virus post-transcriptional regulatory element (WPRE) as a posttran-
scriptional regulatory element in the 3′-untranslated region of the
ORF significantly enhances transgene expression.272
Similar to other viral vectors, achieving tissue or cell-type
specificity is a key component for designing efficient and safe
lentiviral vectors. Numerous tissues or cell types have been
specifically targeted by employing tissue-specific promoters to drive
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transgene expression.273,274 For instance, temporal regulation of
lentiviral vector expression can be achieved by using tetracycline-
inducible promoters.275 In addition, cell-specific targeting can be
improved by utilizing endogenous miRNAs to posttranscriptionally
regulate transgene expression, thereby reducing immune response
mounted against the transgene.156 Pseudotyping has paramount
importance to the success of transducing the desired cell or tissue
type. For example, lentivirus pseudotyped with glycoproteins of
simian immunodeficiency virus and Ebola virus have improved
transduction to the retina and hematopoietic stem cells (HSCs),
respectively.276,277
Production platforms. Large-scale good manufacturing practice
(GMP) of lentiviral vectors for clinical application involves intricate
production, purification, and quality assessment steps. The
process of lentiviral vector production can be roughly divided
into upstream production and downstream purification proce-
dures. For clinical applications, viral production of third-generation
vectors can be achieved by quadruple plasmid transfection with
the transfer vector, along with the three separate plasmids
carrying packaging and helper genes.278–280 HEK293 or HEK293T
producer cell lines are routinely used. Although the HEK293T cell
line is preferred, as it confers higher viral titers,278,281 the HEK293T
line carries the oncogenic simian vacuolating virus 40 large T
antigen, which poses safety concerns. Although the four-plasmid
transfection method is highly modular, batch-to-batch variability
in viral titers remains a challenge.
Alternatively, lentivirus vectors can be manufactured by using a
stable producer cell line that harbors functional lentiviral helper
and packaging genes. In such stable producer cell lines,
tetracycline-inducible systems are customarily used to control
VSV-G and gag-pol expression, which would otherwise be toxic to
cells.282,283 Pseudotyping with VSV-G also enhances the stability of
the viral particle during vector manufacturing.284,285 Cumate- and
tetracycline-inducible systems have been concomitantly used to
limit leaky viral protein expression.286,287 In addition to inducible
stable cell lines, constitutive packaging cell lines have been
developed for a number of envelope proteins that are less toxic
than VSV-G, such as cocal288 and RD114-TR.289 The use of
producer cell lines has an edge over transient transfection
methods in terms of cost, reproducibility, and scalability. However,
it can be cumbersome to produce a stable cell line for each
pseudotyping envelope protein and helper gene combination.
Suspension cell culture production is becoming a widely adopted
method for scalable large-scale lentiviral manufacturing because of
its superiority over adherent cell culture production schemes.
Different cell clones amenable for suspension culture system have
been developed.287,290 Serum-free media is commonly used for
GMP-manufacturing of large-scale vector intended for clinical use, as
this reduces biological contaminants inherent to sera.291,292 In
downstream processes, initial centrifugation and filtration steps help
to remove cellular debris. These procedures are followed by
purification of viral particles with various chromatographic techni-
ques. Buffer exchange and viral particle concentration can be carried
out by ultracentrifugation and tangential flow filtration.293–295 The
purification process needs to be optimized for each pseudotyping
strategy. Large-scale production of lentiviral vector for clinical
application needs to be in compliance with current GMPs (cGMPs),
which include the use of cGMP-certified reagents and manipulation
under aseptic conditions.
Therapeutic lentiviral vectors and commercial availability. The HIV
virus has killed about 32 million people to date (www.who.int/
gho/hiv/en/). In transforming this lethal pathogenic virus into a
delivery vehicle for gene therapy, we have come a long way
towards understanding lentiviruses. For instance, in recent years,
ex vivo applications for lentiviruses in the form of generating
chimeric antigen receptor (CAR) T cells for cancer immunotherapy
have revolutionized how cancer is treated.
Engineered CAR-T cells have been developed to specifically
target cancer-related antigens. The use of lentiviral vectors is
critical for developing CAR-T cells to treat refractory hematologic
malignancies. This approach has been demonstrated in a safety
assessment clinical trial that involved 30 children and adult
patients with relapsed and refractory acute lymphoblastic
leukemia (ALL).296 In these patients, autologous T cells were
transduced with lentiviral vectors carrying a transgene to express
a CAR that binds CD19. The study showed that a remission rate as
high as 90% could be achieved in patients who underwent the
CAR-T cell infusion treatment.296 Going by the commercial name
Kymriah, the treatment later became the first drug to be approved
by the FDA to treat pediatric B-cell ALL. The second CAR-T cell-
based drug approved by the FDA for the treatment of refractory
large B cell lymphoma, named Yescarta, uses gammaretrovirus to
stably deliver the CAR gene construct to cells.297
Lentiviral vectors in clinical trials. Lentiviral vectors have been
tested in many successful clinical trials. The first endeavor
employed a lentiviral vector to treat HIV-positive patients via
ex vivo transduction of patients’ CD4 cells by antisense sequence
against the wild-type HIV viral envelope gene.298 The study
demonstrated that the vector lowered viral load and did not result
in any major adverse effects. To date, there are more than a dozen
completed clinical trials that have used lentiviral vectors for
Fig. 5 Third-generation HIV-1-based lentiviral vector design. The third generation of lentiviral vectors are produced using four plasmids.
The first plasmid has a construct carrying the gene of interest driven by a desired promoter flanked by long terminal repeats (LTRs). Both 5′
and 3′ LTRs in wild-type HIV-1 is composed of U3, R, and U5 sequences. The U3 sequence constitutes promoter/enhancer elements. Part of the
U3 sequence in the 3′-LTR is deleted, and the entire U3 sequence within the 5′-LTR is replaced by a strong viral promoter, such as CMV. The psi
(ψ) packaging signal is followed by the rev response element (RRE). The envelope glycoprotein is encoded by VSV-G (vesicular stomatitis virus)
and is expressed under a strong promoter, such as CMV. The rev gene is split from the packaging plasmid and is provided on a separate
plasmid construct. The packaging plasmid harbors the viral gag and pol genes, and notably lacks the tat regulatory gene
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treating a range of diseases, including metabolic disorders, cancers,
immune disorders, and rare congenital diseases (Table 3). More-
over, due to its safety profile compared to other retroviruses, the
number of ongoing trials that use lentiviral vector is dramatically
increasing.
In particular, the use of lentiviruses in ex vivo gene therapy
strategies for treating genetic diseases have enjoyed substantial
advancements. For example, 18 β-thalassemia patients carrying
mutations in the HBB globin gene received infusion of autologous
CD34+ cells transduced with lentiviral vectors encoding the human
βA-T87Q-globin gene in phase I/II studies.299 The treatment proved
to be successful in replacing long-term allogeneic hematopoietic cell
transplantations. In patient follow-ups, there were no significant
toxicity effects related to the vector after three years post infusion.
This effort has led to the development of LentiGlobinBB305, which
has now advanced to a multinational phase III clinical trial for the
treatment of β-thalassemia (NCT03207009 and NCT02906202) and
sickle cell disease (NCT04293185). Similarly, a lentiviral based gene
therapy approach has shown promising results for the treatment of
cerebral adrenoleukodystrophy, which typically has a very poor
prognosis without allogeneic hematopoietic stem cell transplanta-
tion (HSCT). Nearly 90% of cerebral adrenoleukodystrophy patients
who received hematopoietic stem cells transduced with lentiviral
vectors carrying the ABCD1 transgene have overcome major
functional impairment.300 No genotoxicity or adverse effects related
to the treatment have been reported for any of the test subjects.
Table 3. A selection of ongoing and completed clinical trials employing lentiviral vector
Condition Intervention Sponsor/collaborators Trial stage NCT number
Acute lymphoblastic leukemia CART-19 T cells Union Stem Cell & Gene Engineering Co.
Ltd, Juventas Cell Therapy Ltd
Phase I NCT02975687
University of Pennsylvania NCT01029366
University of Pennsylvania Phase II NCT02030847
ADA-SCID Autologous EFS-ADA LV CD34
+ cells
Orchard Therapeutics, NIAID, NHGRI,
NHLBI, UCLA
Phase I/II NCT01852071
Orchard Therapeutics, UCLA Phase III NCT04140539
NHGRI, UCLA, Duke University, NCI, CC Phase I NCT02022696
Orchard Therapeutics, CIRM, UCLA Phase I/II NCT02999984
NHS Foundation Trust, Orchard
Therapeutics
Phase I/II NCT01380990
Age-related macular degeneration Endostatin and
Angiostatin LV
Oxford BioMedica Phase I NCT01301443
Non-Hodgkin lymphoma CART-19 T cells Peking Union Medical College Hospital,
Cellular Biomedicine Group Ltd
Phase I NCT03483688
Cerebral adrenoleukodystrophy (CALD) Autologous ABCD1 LV CD34
+ cells
Bluebird Bio Phase II/III NCT01896102
β-Thalassemia Autologous βA-T87Q-globin
LV CD34+ cells
Bluebird Bio Phase I/II NCT01745120
Bluebird Bio Phase III NCT03207009
NCT02906202
β-Thalassemia major, sickle cell disease Autologous βA-T87Q-globin
LV CD34+ cell
Bluebird Bio Phase I/II NCT02151526
Sickle cell disease Autologous βA-T87Q-globin
LV CD34+ cells
Bluebird Bio Phase III NCT04293185
Fanconi anemia Autologous FANCA LV CD34
+ cells
Hospital Universitari Vall d’Hebron Research
Institute, CIEMAT, CIBERER
Phase II NCT02931071
HIV infection Autologous C34-CXCR4 LV
CD4 T cells
University of Pennsylvania Early Phase I NCT03020524
Wt gag-TCR and α/6-gag-TCR-
modified T cells
University of Pennsylvania, Adaptimmune Phase I NCT00991224
HIV antigen LV Theravectys S.A. Phase I/II NCT02054286
Lymphoma rHIV7-shI-TAR-CCR5RZ
LV HPCs
City of Hope Medical Center, NCI Phase I NCT00569985
Multiple myeloma CART-19 T cells University of Pennsylvania Phase I NCT02135406
Refractory diffuse large B-cell lymphoma CART-19 T cells Cellular Biomedicine Group Ltd, Nanjing
Medical University
Phase I NCT02976857
Covid-19 infection SARS-CoV-2 antigen in aAPC Shenzhen Geno-Immune Medical Institute Phase I NCT04299724
Wiskott–Aldrich syndrome Autologous WAS LV CD34
+ cells
Genethon, Hôpital Necker-Enfants Malades Phase I/II NCT01347346
Genethon, NHS Foundation Trust, Institute
of Child Health
Phase I/II NCT01347242
ADA-SCID adenosine deaminase severe combined immunodeficiency, CART-19 T chimeric antigen receptor 19 T cells, CC National Institutes of Health Clinical
Center, EFS-ADA elongation factor 1α promoter driving adenosine deaminase, FANCA Fanconi anemia complementation group gene, HIV human
immunodeficiency viruses, HPCs hematopoietic progenitor cells, LV lentiviral vector, NCI National Cancer Institute, NHGRI National Human Genome Research
Institute, NHLBI National Heart, Lung, and Blood Institute, NIAID National Institute of Allergy and Infectious Diseases, SARS-CoV-2 severe acute respiratory
syndrome coronavirus, TCR T-cell receptor, UCLA University of California Los Angeles, WAS Wiskott–Aldrich syndrome gene, wt wild type.
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Ex vivo gene therapy has also been a viable alternative to
allogeneic HSCT treatment of inherited primary immune deficiency
disorders. To this end, lentiviral gene therapy has been demon-
strated to be safe in patients with ADA-SCID that is caused by a
mutation in the ADA gene. In a non-randomized clinical trial
conducted at two different sites in the USA, 30 pediatric ADA-SCID
patients were infused with autologous CD34+ hematopoietic stem/
progenitor cells transduced with lentiviral vectors containing the
ADA transgene.301 With the exception of one patient exhibiting non-
engraftment, all other patients were taken off of enzyme replace-
ment therapy and showed event-free survival beyond two years
post treatment. Following this success, the lentiviral vector drug
named OTL-101, entered a phase III clinical trial for the treatment of
ADA-SCID (NCT04140539). In another primary immune deficiency
disorder, eight pediatric patients with Wiskott–Aldrich syndrome
were infused with autologous CD34+ transduced with a lentiviral
vector carrying the WAS transgene. Interim analysis at 3.6 years post
treatment showed an overall 100% survival rate with improved
immunity and removal from immunoglobulin supplementation for
seven of the eight treated patients.302
In comparison to gammaretroviral vectors, lentiviral vectors are
preferentially used in many advanced (phase III) clinical trials for CAR-
T-cell therapies. Ongoing phase III clinical trials for CAR-T cells
targeting refractory B-cell lymphoma (NCT03391726), ALL
(NCT03027739 and NCT03937544), and refractory B-cell acute myeloid
leukemia (NCT03631576) were developed by lentiviral vectors.
Engineering of T-cell receptors (TCRs) to specifically recognize
cancer-specific proteins is another cancer immunotherapy approach
being explored. In a preclinical study, lentiviral vectors were
successfully used to transduce hematopoietic stem cells with NY-
ESO-1 TCR, with no measurable genotoxicity.303 A recently reported
clinical trial indicated that a TCR targeting the NY-ESO-1 antigen in
multiple myeloma patients had good efficacy and minimal toxicity
(NCT01352286).304
Lentiviral vectors are also being tested to tackle viral infection
including the development of novel vaccines against COVID-19.
In two recently launched clinicals, lentiviral vectors are being used
to express synthetic viral minigenes and immune modulatory genes
to engineer artificial APCs to activate the immune system against
COVID-19 (NCT04299724).
Challenges. An early clinical trial that used a gammaretroviral
vector to treat X-linked SCID led to serious adverse effects.305 Four
out of the nine patients who received the treatment went on to
develop T-cell leukemias, as a result of insertional mutagenesis.
Thus, lentiviral vectors have become the preferred vehicle for
transgene delivery, owing to their reduced genotoxicity profile
when compared to gammaretroviral vectors.306–308 Although both
vectors preferentially integrate into transcriptionally active
regions, one possible factor contributing to differences in
genotoxicity is that gammaretroviral vectors often integrate
within the vicinity of transcriptional start sites, and has affinities
toward oncogenes.307,309–311 The use of third-generation, self-
inactivating lentiviral vectors have helped to mitigate the risk of
insertional mutagenesis.269 Nonetheless, it has been reported that
even self-inactivating lentiviral vectors with strong promoter and
enhancer elements can activate neighboring genes. Incorporation
of insulator sequences to neutralize the effect of enhancers acting
in trans can reduce these effects.312–315 In addition, integration
can potentially form chimeric gene fusions made up of proviral
and host sequences.316–318 Finally, lentiviral vectors have been
shown to cause aberrant splicing of cellular transcripts.318,319
The future for lentivirus vectors. The number of viral vectors being
developed as delivery platforms for genetic vaccines is increasing.
Due to their ability to transduce non-dividing cells, such as
dendritic cells, recombinant lentiviral vectors have been shown to
elicit B cell- and T cell-mediated immunity against infectious
diseases and different tumors.320 Recent advances in the
development of non-integrating lentiviral vectors have greatly
reduced insertional mutagenesis.321 Another advantage of non-
integrating lentiviral vectors is their transient expression in
actively dividing cells, where sustained transgene expression is
not necessary. Application of non-integrating lentiviral vectors to
circumvent immune responses mounted against prolonged
expression of genome editing tools, such as CRISPR/Cas, facilitates
the use of such systems in therapeutic gene editing.322 In addition
to non-integrating lentiviruses, self-restricted CRISPR systems with
shortened duration of cas9 expression, could reduce off-target
effects and enhance CRISPR-based therapeutics.323
Integrase-defective lentiviral vectors have been designed as a
vaccine platform to deliver vaccination against influenza and
malaria antigens.324,325 Such lentiviral vectors are being continu-
ously developed and optimized, and could enjoy a broader
application in future gene therapies. In addition, the development
of safer vectors via photo-switchable non-canonical amino acids
to regulate transgene expression in a spatial and temporal
manner,326 also represent the next generation of lentiviral vectors.
Lentiviral vector has become one of the preferred tools for
ex vivo transgene delivery for gene therapy, because it has many
attractive features. These vectors have proven to be invaluable for
ex vivo gene correction and gene transfer. Lentiviral vector
systems have evolved a great deal and are increasingly being
improved. This effort will result in wider adoption of lentiviral
vectors to treat human diseases.
CLOSING REMARKS
In this review, we have discussed the current state of viral vectors,
specifically those based on Ad, AAV, and lentivirus. It is abundantly
clear that the future for viral-based vectors is bright and the ability
to address many human genetic diseases is within reach.
Unfortunately, the current tools at our disposal are still wrought
with complications, and for many diseases, a long path awaits
until viable treatments are available. Further exploration into viral
biology, as well as advanced and interdisciplinary approaches are
needed to overcome the current challenges that still curb the
promise for the numerous vector platforms currently in preclinical
and clinical testing phases. What the past 30 years has taught us is
that every great idea has unexpected pitfalls. Nevertheless, every
obstacle that is faced and overcome gifts us with a clearer sense of
where our goals towards improving human health are set.
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